/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Biohumoral and echocardiographic correlates of tafamidis treatment in transthyretin cardiac amyloidosis
Event: Heart Failure 2023
Topic: Clinical
Session: Novelties in amyloid cardiomyopathy
Prognostic value of sST2 in heart failure patients with diabetes
Event: Heart Failure 2021
Topic: Biomarkers
Session: ePoster session
High-sensitivity cardiac troponin T and NT-proBNP for ruling-in and ruling-out of cardiac amyloidosis
Event: ESC Congress 2020
Topic: Infiltrative Myocardial Disease
Session: Advances in the Diagnosis and Treatment of Cardiac Amyloidosis
Biopsy evidence of dual amyloidosis in the same patient: diachronous cardiac involvement by transthyretin and immunoglobulin light chains.
Event: ESC Congress 2020
Topic: Clinical
Session: Amyloidosis
NT-proBNP and high-sensitivity cardiac troponin T to diagnose cardiac amyloidosis
Event: ESC Congress 2019
Topic: Infiltrative Myocardial Disease
Session: Inflammatory and infiltrative cardiomyopathy
Soluble suppression of tumorigenicity-2 in cardiac amyloidosis, hypertrophic and dilated cardiomyopathy
Event: Heart Failure 2019
Topic: Clinical
Session: Rapid Fire 7 - Improving our insights: biomarkers, imaging, scores
Differences in circulating cardiac biomarkers between immunoglobulin light-chain and transthyretin cardiac amyloidosis
Event: Heart Failure 2019
Topic: Clinical
Session: Rapid Fire 6 - Risk stratification and prognosis
ESC 365 is supported by
